Journal of Clinical Oncology, Vol 15, 2966-2973, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy

WS Lofters, JL Pater, B Zee, E Dempsey, D Walde, JP Moquin, K Wilson, P Hoskins, RM Guevin, S Verma, R Navari, JE Krook, J Hainsworth, M Palmer and C Chin
Kingston Regional Cancer Centre, and National Cancer Institute of Canada Clinical Trials Group, Ontario.

PURPOSE: To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to evaluate the efficacy when dexamethasone is added to either drug in the first 24 hours; and to extend these comparisons over 7 days in patients receiving moderately emetogenic chemotherapy. PATIENTS AND METHODS: This was a multicenter, double-blind, randomized study with six parallel arms that used a 2 x 2 factorial design in chemotherapy-naive patients. In arm 1, dolasetron (2.4 mg/kg) was given intravenously (I.V.) prechemotherapy, followed 24 hours later by oral dolasetron (200 mg once daily) for 6 days. Arms 2 and 3 consisted of dolasetron and dexamethasone 8 mg I.V., followed 24 hours later by oral dexamethasone (8 mg once daily) in one arm, and oral dexamethasone and dolasetron in the other, also for 6 days. In arms 4, 5, and 6, ondansetron (32 mg I.V. or 8 mg orally twice daily) was administered in a similar manner to arms 1, 2, and 3 before and 24 hours after chemotherapy. Mean nausea severity (MNS) was assessed on a visual analog scale (VAS) in a daily diary. RESULTS: Of 703 patients enrolled, 696 were eligible. There were 343 dolasetron- and 353 ondansetron-treated patients; 57% of dolasetron- treated patients had complete protection in the first 24 hours versus 67% of patients who received ondansetron (P = .013). MNS was also more pronounced on the dolasetron arm (P = .051). Sixty-seven percent of patients who received added dexamethasone in the first 24 hours had complete protection, compared with 55% without dexamethasone (P < .001). MNS was significantly reduced with the addition of dexamethasone (P < .001). At 7 days, dolasetron and ondansetron had equivalent complete protection rates (36% and 39%, respectively). With the addition of dexamethasone, 48% of patients compared with 28% had complete protection (P < .001). MNS was significantly improved with added dexamethasone (P < .001). CONCLUSION: At the doses used, dolasetron was significantly less effective than ondansetron at controlling nausea and vomiting in the first 24 hours in patients receiving moderately emetogenic chemotherapy, but there was no demonstrable difference between both drugs over 7 days. The addition of dexamethasone significantly improved the efficacy of both drugs in the first 24 hours and over 7 days.

This article has been cited by other articles:

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				D. G. Warr, P. J. Hesketh, R. J. Gralla, H. B. Muss, J. Herrstedt, P. D. Eisenberg, H. Raftopoulos, S. M. Grunberg, M. Gabriel, A. Rodgers, et al. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2822 - 2830. [Abstract] [Full Text] [PDF]

				M. Constenla 5-HT3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis Ann. Pharmacother., October 1, 2004; 38(10): 1683 - 1691. [Abstract] [Full Text] [PDF]

				R. M Navari and J. M Koeller Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists Ann. Pharmacother., September 1, 2003; 37(9): 1276 - 1286. [Abstract] [Full Text] [PDF]

				P. Ellis and N. Dozier Evidence for Equivalent Electrocardiographic Changes Among the 5-HT3 Receptor Antagonists Oncologist, April 1, 2003; 8(2): 216 - 218. [Full Text] [PDF]

				S. Goodin and R. Cunningham 5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile Oncologist, October 1, 2002; 7(5): 424 - 436. [Abstract] [Full Text] [PDF]

				D. L. Keefe The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern? Oncologist, February 1, 2002; 7(1): 65 - 72. [Abstract] [Full Text] [PDF]

				J. P. A. Ioannidis, P. J. Hesketh, and J. Lau Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence J. Clin. Oncol., October 19, 2000; 18(19): 3409 - 3422. [Abstract] [Full Text] [PDF]

				A. W. Valley A review of dolasetron as management of nausea and vomiting in cancer patients Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S28 - S40. [Abstract] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]